Compare SGC & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGC | CRDF |
|---|---|---|
| Founded | 1920 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.7M | 130.7M |
| IPO Year | 1994 | 2012 |
| Metric | SGC | CRDF |
|---|---|---|
| Price | $9.98 | $1.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $16.00 | $9.63 |
| AVG Volume (30 Days) | 36.6K | ★ 689.6K |
| Earning Date | 03-03-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.47% | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $566,184,000.00 | $365,993.00 |
| Revenue This Year | $3.23 | N/A |
| Revenue Next Year | $3.82 | N/A |
| P/E Ratio | $22.35 | ★ N/A |
| Revenue Growth | 0.09 | ★ 49.61 |
| 52 Week Low | $8.30 | $1.48 |
| 52 Week High | $13.78 | $4.56 |
| Indicator | SGC | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 47.30 | 43.24 |
| Support Level | $9.73 | $1.51 |
| Resistance Level | $10.49 | $2.05 |
| Average True Range (ATR) | 0.42 | 0.12 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 23.47 | 16.92 |
Superior Group Of Companies Inc designs apparel products. The company operates through three segments: i) The Branded Products segment, under the brands BAMKO and HPI, produces and sells customized merchandising solutions, promotional products, and branded uniform programs. ii) The Healthcare Apparel segment, under the brands Wink and Fashion Seal Healthcare, manufactures and sells healthcare apparel including scrubs, lab coats, protective apparel, and patient garments. iii) The Contact Centers segment, through The Office Gurus entities, provides outsourced, nearshore, and onshore business process outsourcing (BPO), contact center, and call-center support services to customers in North America. The majority of the company's revenue is derived from the Branded Products segment.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.